Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2020.06.03.20121582: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Detection of anti-SARS-CoV-2 antibody response: Antibodies against SARS-CoV-2 were measured using indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) using SARS-CoV-2 receptor-binding domain (RBD) as the antigen. SARS-CoV-2suggested: NoneSARS-CoV-2 receptor-binding domain (RBDsuggested: NoneExperimental Models: Cell Lines Sentences Resources The RBD antigen was produced by transient transfection of RBD plasmid to Vero E6 … SciScore for 10.1101/2020.06.03.20121582: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Detection of anti-SARS-CoV-2 antibody response: Antibodies against SARS-CoV-2 were measured using indirect immunofluorescence assay (IFA) and enzyme-linked immunosorbent assay (ELISA) using SARS-CoV-2 receptor-binding domain (RBD) as the antigen. SARS-CoV-2suggested: NoneSARS-CoV-2 receptor-binding domain (RBDsuggested: NoneExperimental Models: Cell Lines Sentences Resources The RBD antigen was produced by transient transfection of RBD plasmid to Vero E6 cells and the produced protein was purified following established protocol (Stadlbauer et al., 2020). Vero E6suggested: NoneResults from OddPub: Thank you for sharing your data.
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
-